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Abstract
Cardiovascular circulation and kidney function are closely interrelated. The impairment of renal 
function is a well-known hazard of increased mortality and morbidity of patients with heart failure or 
coronary artery disease. Acute pulmonary embolism (APE) impacts pulmonary and systemic circula-
tion, and can severely impair functions of other organs, including kidneys, as a result of hypoxemia and 
increased venous pressure. 
Previous studies indicate that renal dysfunction predicts short- and long-term outcomes and can im-
prove the risk assessment in APE. However, renal function should also be cautiously considered during 
the diagnostic workup because the contrast-induced nephropathy after computed tomography pulmonary 
angiography is noticed more frequently in APE. Chronic thromboembolic pulmonary hypertension 
(CTEPH) is a rare but imminent complication of APE. This condition promotes renal impairment by 
increasing venous pressure and decreasing glomerular filtration. The renal function improvement and 
serum creatinine concentration reduction were noted in CTEPH subgroup with glomerular filtration 
rate ≤ 60 mL/min/1.73 m2 after successful treatment.
In this review, we present the essential research results on the kidney function in thromboembolism 
disease. (Cardiol J)
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Introduction
Cardiovascular diseases are the most fre-
quent causes of morbidity and mortality in the 
general population, and impaired renal function is 
a broadly known risk factor increasing mortality 
[1]. The association between kidney function and 
diseases of heart and vessels seems to be obvious. 
Approximately 4.5% of the general population has 
a glomerular filtration rate (GFR) < 60 mL/min [2], 
which puts them at risk.
To assess renal function, serum plasma creati-
nine and GFR are the most widely used. However, 
the direct measurement of GFR is usually avoided, 
and its estimations based on the modification of 
Diet in Renal Disease (MDRD) [3] and the Cock-
croft-Gault (C–G) formula [4] are convenient and 
accurate substitutes.
Acute pulmonary embolism (APE) does not 
only have an impact on pulmonary but also sys-
temic circulation and can impair functions of other 
organs causing hypoxemia and increased venous 
pressure. It should be underlined that kidneys are 
susceptible to hypoxemia [5]. The previous studies 
indicate that renal dysfunction predicts short- and 
long-term outcomes and can improve the risk as-
sessment in APE [6, 7]. However, kidney function 
and its assessment are essential in various throm-
boembolic disease. 
At diagnosis 
In patients with high clinical probability and 
abnormal D-dimer levels, computed tomography 
pulmonary angiography (CTPA) is performed not 
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tain information about possible right ventricle (RV) 
dysfunction [8]. Nevertheless, CTPA can trigger 
contrast-induced acute kidney injury (CI-AKI) [9], 
which is usually defined as an increase of creatinine 
level ≥ 0.5 mg/dL or > 25% from baseline within 
48 hours of contrast usage [10]. Some studies have 
suggested that APE patients are more vulnerable 
to, and more frequently experience, CI-AKI. Firstly 
APE is a condition leading to impairment of renal 
function. As a consequence of thrombi closure 
and vasoconstriction of the pulmonary arteries, 
pulmonary resistance rises, and subsequently the 
pressure in the RV also increases. Hemodynamic 
destabilization of the RV effects a reduction in left 
ventricular load and, consequently, a reduction 
in stroke volume and systemic hypotension [11]. 
Because the RV is not adapted to sudden pressure 
overloads, its failure occurs, which results in con-
gestion in the peripheral circulation. The increase 
of a central venous pressure leads to a stagnation of 
blood in central veins and subsequent passive hy-
peremia of liver and kidneys [12]. Elevated central 
venous pressure, hypoxemia and decreased cardiac 
output results in organ hypoperfusion [13] and can 
be a factor in renal dysfunction [14]. Coexisting hy-
poxemia is a result of pulmonary circulatory failure 
and leads to ischemic damage [15]. Kidneys are 
among the most sensitive organs to hypoxemia [5]. 
Increased venous pressure causes a reduction of 
trans-glomerular pressure gradients and impairs 
kidney perfusion. This mechanism also activates the 
renin-angiotensin-aldosterone system (RAAS) and 
the sympathetic nervous system leading to oxygenic 
stress and further renal function impairment.
Moreover, as a consequence of respiratory 
failure, a lower level of pH and bicarbonate is 
observed in arterial blood. This state promotes 
the production of reactive oxygen species, which 
aggravate already present ischemic damage. One 
of the suspected mechanisms of CI-AKI is also an 
ischemic injury of the renal medulla and production 
of reactive oxygen species, which damage tubules 
and endothelium [16]. We can conclude that all of 
APE’s pathophysiological consequences promote 
kidney dysfunction and the occurrence of CI-AKI. 
Kooiman et al. [17], in a group of 237 patients 
with suspicion of pulmonary embolism, studied 
the frequency and risk factors of contrast-induced 
nephropathy (CIN) after CTPA. The prevalence of 
CIN was 8.9%. Independent predictors of impaired 
renal function after contrast administration were 
age over 75 years, diabetes mellitus, non-steroidal 
anti-inflammatory drug use, and multiple myeloma. 
Doganay et al. [18], in a retrospective study of 122 
patients with confirmed APE, showed that the in-
cidence of CI-AKI is more frequent in APE than in 
other conditions examined with contrast-enhanced 
computed tomography, 13% vs. 3–4%, respectively. 
The logistic regression analysis confirmed lower 
pH in arterial blood gas and older age as the risk 
factors of CI-AKI. Other remarkable hazards were 
chronic heart failure, higher pressure in pulmonary 
artery estimated in transthoracic echocardio-
graphy, administration of angiotensin converting 
enzyme inhibitors (ACE-I) or angiotensin receptor 
blocker (ARB), and low HCO3–. Some of these fac-
tors, like age, chronic heart failure, and treatment 
with ACE-I or ARB, can be found in the risk score 
scale created by Mehran et al. [19] for patients after 
a coronary intervention. However, additional haz-
ards are more frequent in patients with APE, espe-
cially high and moderate-high risk class according 
to the European Society of Cardiology (ESC) [8]. 
Summarizing, there is a remarkable overlap of 
the risk factors between the CIN risk score [19] 
and the APE risk score [20]. Consequently, Ho 
and Harahsheh [21] created the study comparing 
CIN risk score and pulmonary embolism severity 
index (PESI) in the prediction of renal insufficiency 
in critically ill patients suspected on APE. They 
included 137 intensive care unit (ICU) patients with-
out end-stage renal failure. The study revealed that 
CIN risk score was significantly better than PESI 
in the prediction of CIN leading to dialysis (area 
under curve [AUC] 0.864, 95% confidence interval 
[CI] 0.795–0.916 vs. 0.731, 95% CI 0.649–0.804; 
p = 0.001, respectively). However, PESI had the 
advantage of better survival prognosis (AUC 0.794, 
95% CI 0.716–0.858 vs. 0.625, 95% CI 0.538–0.706; 
p = 0.001). The authors suggested that in critically 
ill patients with suspicion of APE and high risk of 
CIN, other diagnostic methods should be considered 
instead of CTPA. Michell et al. [22] showed that after 
CTPA the frequency of CIN is higher than after other 
contrast procedures, at 14% vs. 10%, respectively.
Additionally, the prevalence of CIN was related 
to increased risk of poor outcome, such as severe 
renal failure and death (16% of patients with CIN 
after CTPA). The guidelines of the Contrast Me-
dium Safety Committee 2018 [23] recommend 
hydration (saline or sodium bicarbonate) to prevent 
CI-AKI in patients at risk of this complication. 
In a randomized control trial, Turedi et al. [24] 
compared the prophylaxis of CIN after CTPA with 
N-acetylcysteine, sodium bicarbonate and saline. 
In the group of 231 patients, 15.2% (32/231) had 
CIN, but none of the prophylaxes was more effec-
tive. The multivariate logistic regression analysis 
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indicated that only basal GFR and the presence of 
hypotension were independent predictors of CIN 
development. Kooiman et al. [25] compared a lack 
of hydration with hydration of 250 mL 1.4% sodium 
bicarbonate in the prophylaxis of CI-AKI after 
CTPA in 138 patients with chronic kidney disease 
(CKD) and suspicion of APE. They did not observe 
differences in the frequency of CI-AKI between 
groups, and suggested that not using pre-hydration 
would avoid a delay in performing CTPA and proper 
diagnosis. Another interesting study is the recent 
Kompas Randomized Clinical Trial [26]. In a group 
of 523 patients with stage 3 of CKD, who under-
went contrast-enhanced computed tomography, no 
hydration was compared with sodium bicarbonate 
administration. The CI-AKI occurred in 11 (2.1%) 
patients. In the no pre-hydration group it was 7 of 
262 (2.7%), and 4 of 261 (1.5%) in the pre-hydration 
group and the relative risk was 1.7 (95% CI 0.5–5.9; 
p = 0.36). The authors concluded that withholding 
hydration is safe and cost-effective. 
During hospitalization  
and after discharge 
The risk stratification of pulmonary embo-
lism patients is crucial in the selection of medical 
management. As previously mentioned, APE im-
pairs not only pulmonary circulation but also the 
systemic circulation and function of many organs, 
including kidneys, the dysfunction of which may 
negatively influence the outcome. 
In the ICOPER study, creatinine > 177 µmol/L 
predicted 3-month mortality [27]. The authors of 
the Hestia study indicated that the diagnosis of 
APE in patients with creatine clearance < 30 mL/ 
/min (C–G) should be the premise for in-hospital 
treatment [28]. The studies conducted in our de-
partment revealed that renal dysfunction predicted 
short and long-term outcome and could be useful 
in improving the risk assessment in APE [6]. In 
a group of 2247 APE patients hospitalized in three 
European centers, GFR ≤ 60 mL/min/1.73 m2 cal-
culated by MDRD was a risk factor of mortality 
during 30- and 180-day observation. Moreover, the 
inclusion of GFR ≤ 60 mL/min/1.73 m2 enhanced 
the ESC risk stratification model, with a net re-
classification index (NRI) of 0.42. The impaired 
kidney function, assessed as a drop in eGFR, was 
also linked with a higher occurrence of bleeding 
(odds ratio [OR] 0.90 per 10 mL/min/1.73 m2, 
95% CI 0.85–0.95; p = 0.0002). The analysis of the 
same group of patients showed no significant differ-
ence in mortality prediction between the two GFR 
estimation formulas: C–G vs. MDRD. The areas 
under the receiver operating characteristics curves 
for both the methods were similar [29]. 
The comparison of various methods of GFR 
estimation (C–G vs. CKD-EPI) was recently 
performed on data from the RIETE registry [30]. 
Among the 4676 patients with GFR ≤ 30 mL/min 
according to at least one of the formulas, these 
result was not confirmed in 40.7% individuals 
by the other equation. However, patients with 
a diagnosis of severe renal impairment, regard-
less of the method used for GFR calculation, had 
a higher rate of major bleedings during anticoagu-
lation treatment (approximately 10% vs. 4%). In 
the subgroups with low GFR the all-cause mor-
tality rates were higher than in patients without 
severe renal failure.
In another single-center study eGFR ≤ 35 mL/ 
/min in normotensive APE patients was as-
sociated with higher risk of 30-day mortality 
and, when combined with the troponin level, 
also improved risk stratification [7]. Similarly, 
Altinsoy et al. [31] in a multivariate analysis 
demonstrated that GFR estimated by CKD-EPI 
or MDRD coexisting with an elevated troponin 
concentration were independent predictors of an 
adverse outcome in normotensive patients with 
APE. In this study, the GFR also correlated with 
RV dysfunction.
Serum creatine measurement is variable and 
reflects somewhat the functional changes of glo-
merular filtration roughly mirroring kidney injury 
[32]. New markers surpass serum creatinine in 
assessing renal filtration as well as glomerular or 
tubulointerstitial damage. Because of the early 
occurrence of novel renal markers, the diagnosis 
of kidney dysfunction might be suspected before 
any change in creatinine concentration. Neutrophil 
gelatinase-associated lipocalin (NGAL) [33] and 
cystatin C are examples of these compounds [34]. 
A study of APE patients showed that NGAL plasma 
levels were significantly higher in non-survivors 
[35]. Furthermore, increased levels of NGAL and 
cystatin C in patients with APE were associated 
with higher 30-day all-cause, pulmonary embolism-
related, and 180-day mortality. The elevation of 
NGAL in a group with low risk of death due to 
APE had 100% negative predictive value for 30-day 
all-cause death. Plasma concentration of cystatin C 
was the most significant predictor of death in mul-
tivariable analysis. Even though novel biomarkers 
seem to be more precise than those based on serum 
creatinine GFR, they are rarely available and are 
not commonly used (Table 1). 
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Long-term follow-up after  
an APE episode
Chronic thromboembolic pulmonary hyperten-
sion (CTEPH) is one of the subtypes of pulmonary 
hypertension (PH) [36]. The epidemiology of 
this disease is barely known. In a meta-analysis 
of 16 studies on CTEPH, its pooled incidence in 
unselected patients after APE during 2–3 years of 
follow-up was 0.56% [37]. Researchers observed 
that among survivors, the frequency of CTEPH 
was 3%. Clinical practice suggests that this mor-
bidity rate may be more accurate. The CTEPH 
is considered to develop as a consequence of the 
impaired resolution of pulmonary thrombi, which 
subsequently become endothelized. This leads 
to chronic obstruction of the pulmonary arteries, 
high pulmonary vascular resistance, increased 
pressure in the pulmonary circulation, and pro-
gressive right heart failure [12]. In patients with 
CTEPH, impairment of kidney function also plays 
an important role. Chronic elevation of central 
venous pressure secondary to RV dysfunction 
runs to high renal venous pressure [38] and a drop 
in effective filtration pressure [39]. That process 
activates neurohormonal ways, including RAAS, 
and pro-inflammatory pathways, which further 
decline the filtration fraction [40]. The activation 
of the RAAS also leads to oxidative kidney injury 
[41, 42]. Additionally, PH worsens the course of 
CKD [43]. This is associated with a state of el-
evated catecholamine levels, activation of RAAS, 
and progressive RV dysfunction [44, 45]. The 
above cascade deteriorates PH. Summarizing, the 
impaired renal function may be a consequence of 
PH but also might be a reason for PH exacerbation 
[46]. Nevertheless, PH is associated with higher 
mortality in patients with CKD [47].
Chronic thromboembolic pulmonary hyper-
tension is a complication of pulmonary embolism, 
with abysmal prognosis if left untreated [48]. The 
first-choice treatment is the surgical removal of 
Table 1. Overview of important studies on renal function impairment in acute pulmonary embolism (APE).
Study or author’s 
name
Year Patients  
group
Main results
ICOPER study [27] 1999 2454 Creatinine > 177 µmol/L predicts 3-month mortality
Kostrubiec el al. [7] 2010 220 eGFR ≤ 35 mL/min in normotensive APE  
patients increases the risk of 30-day mortality 
eGFR combined with troponin level — improves  
the risk stratification
Kostriubiec et al. [35] 2012 142 NGAL plasma level was significantly higher in non-survivors  
Increase level of NGAL and cystatin C — higher rate of 30-day  
all-cause and pulmonary embolism-related mortality,  
and 180-day mortality 
Cystatin C — most significant predictor of death in  
multivariable analysis
Hestia study [28] 2013 496 APE patients with eGFR < 30 mL/min (C-G) as an indicator  
of in-hospital treatment
Altınsoy et al. [31] 2017 99 GFR (CKD-EPI or MDRD) with elevated troponin is  
an independent predictor of adverse outcome  
in normotensive APE 
GFR correlated with right ventricle dysfunction
Ho and Harahsheh [21] 2018 137 CIN risk score is significantly better than PESI in  
the prediction of CIN leading to dialysis  
PESI has the advantage of better survival prognosis
Kostrubiec et al. [6] 2019 2247 GFR ≤ 60 mL/min/1.73 m2 (MDRD) is a risk factor  
of 30- and 180-day mortality 
GFR ≤ 60 mL/min/1.73 m2 enhanced the European Society  
of Cardiology risk stratification 
Lower eGFR is associated with higher occurrence of bleeding
Catella et al [30] 
RIETE study  
sub-analysis 
2019 4676 Severe renal impairment is associated with higher rate  
of major bleedings during anticoagulation 
Low GFR subgroups with higher all-cause mortality
CIN — contrast-induced nephropathy; CKD-EPI — Chronic Kidney Disease Epidemiology Collaboration; eGFR — estimated glomerular filtra-
tion rate; MDRD — modification of diet in renal disease; NGAL — urinary neutrophil gelatinase-associated lipocalin; PESI — pulmonary embo-
lism severity index
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chronic thrombi from pulmonary arteries, i.e. 
endarterectomy (PEA) [49]. PEA is considered 
to be the optimal option but requires a cardiopul-
monary bypass with deep hypothermia and total 
circulatory arrest [50]. The qualification for the 
procedure should be made by a highly specialized 
team. The decision depends on the patient’s profile, 
comorbidities, and thrombi location [36]. The rate 
of operable vs. non-operable patients fluctuates 
40–60% [51]. Successful treatment improves the 
prognosis and quality of life, and results in a better 
renal function [52]. According to the registry of 679 
patients with CTEPH for the whole cohort, PEA 
was the strongest independent predictor of survival 
(HR 0.37; 95% CI 0.24–0.58; p < 0.0001) [51]. The 
analysis of preoperative characteristics of operated 
patients revealed dialysis-dependent renal failure as 
one of the risk factors of death (HR 11.52; 95% CI 
1.42–93.48; p = 0.0221). Other independent risks 
factors of mortality for both the operated and the 
not-operated group were age, New York Heart As-
sociation class, right atrial pressure, history of cancer, 
left heart failure, and dialysis-dependent renal failure. 
However, it should be noted that 12–31% patients 
after PEA have persistent or recurrent PH [53, 54].
Balloon pulmonary angioplasty (BPA) is 
a feasible PEA alternative for patients with high 
perioperative risk, distal location of the lesion, or 
persistent PH [36, 54]. Subsequent percutaneous 
dilatation of occlusions and opening of obstructed 
pulmonary arteries improve the hemodynamic 
status, reduce symptoms, and lead to the decrease 
of cardiomarker levels [55]. Appropriate and multi-
ple BPA results in the reduction of the pulmonary 
vascular resistance (PVR) and mean pulmonary 
artery pressure (mPAP) [56, 57]. The optimal effect 
is usually achieved after 3–10 BPA sessions [48]. 
Every BPA session carries a considerable risk of 
contrast-induced nephropathy. However, Darocha 
et al. [58] described only 2 (0.8%) episodes of CIN 
following 250 BPA procedures in 41 patients, and no 
patient needed dialysis. Of interest, the renal func-
tion improvement and serum creatinine concentra-
tion reduction was noted in the CTEPH subgroup 
with GFR ≤ 60 mL/min/1.73 m2 (12 patients, 29%) 
after BPA treatment. This was accompanied by 
a drop in mPAP, PVR, and N-terminal-pro-B-type 
natriuretic peptide and extension of the distance 
in the 6-minute walking test. The investigators 
noted that a relative increase of GFR, from the 
initiation of BPA therapy throughout the following 
3–6 months after BPA, was correlated with rela-
tive changes of cardiac index, right atrial pressure, 
and mixed venous oxygen saturation. The study 
indicated that the incidence of CIN after BPA was 
a rare complication in comparison to percutaneous 
coronary intervention, despite the higher contrast 
volume. The rationale could be intravenous admin-
istration of contrast and better hemodynamic status 
of patients during BPA [59]. Higher frequency of 
CI-AKI was described by Kriechbaum et al. [60] in 
a group of 51 patients undergoing BPA. The AKI 
occurred after 6 (2.3%) procedures in 5 (9.8%) 
various patients following 265 BPA sessions. In all 
cases, AKI was stage I and no distinctive features 
for these patients from the rest of the study group 
were found. Analysis of the subgroup of patients 
with CKD revealed that renal function improved 
after BPA, which might be related to the improve-
ment of the systemic circulation. Kimura et al. [61] 
Table 2. Overview of important studies on renal function impairment in chronic thromboembolic  
pulmonary hypertension (CTEPH).
Study or author’s name Year Patient group Main results
Delcroix et al. (International 
Prospective Registry) [51]
2016 679 patients  
with CTEPH
Dialysis-dependent renal  
— risk factors of death
Darocha et al. [58] 2019 250 BPA in  
41 patients
Low rate of CIN (0.8%) 
Renal function improvement and creatinine  
reduction after BPA treatment
Kriechbaum et al. [60] 2019 265 BPA in  
51 patients 
CI-AKI occurred after 6 (2.3%) BPA 
Patients with CKD — renal function improved after BPA
Kimura et al. [61] 2015 46 patients  
treated by BPA
Upturn of renal filtration in patients with  
initially impaired kidney function 
Isobe et al. [62] 2019 45 patients Increased of cardiac index and mixed venous oxygen  
saturation with a decrease of mPAP and PVR-predictors  
of renal insufficiency improvement after BPA
BPA — balloon pulmonary angioplasty; CI-AKI — contrast-induced acute kidney injury; CIN — contrast-induced nephropathy; CKD — chronic 
kidney disease; mPAP — mean pulmonary artery pressure; PVR — pulmonary vascular resistance
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observed an upturn of renal filtration in patients 
with initially impaired kidney function in a group 
of 46 patients treated with BPA. Nevertheless, the 
rise of GFR was not significant for the entire study 
group. A recent study by Isobe et al. [62] indicated 
that some hemodynamic parameters, such as an 
increased cardiac index and mixed venous oxygen 
saturation with a decrease of mPAP and PVR, were 
predictors of renal insufficiency improvement in 
patients undergoing BPA. In conclusion, renal func-
tion may be significantly improved after successful 
sessions of BPA due to a drop in venous pressure, 
lower venous congestion in kidneys, and higher 
cardiac output (Table 2). 
Chronic thromboembolic pulmonary hyperten-
sion is not the only type of PH affecting renal function. 
The coexistence of CKD and PH is obviously the most 
common in the most frequent type 2 PH, secondary 
to left heart disease [63]. The presence of PH in pa-
tients with renal insufficiency is associated with high 
all-cause mortality and frequency of cardiovascular 
events [64]. PH is a cause of the rapid progression of 
CKD [65]. Furthermore, CKD exaggerates PH [66].
Research on PH is developing quickly, in-
creasing our understanding of its pathophysiology. 
Subsequent to this evolution, a recent paper by Si-
monneau [67] suggested a change of PH definition 
setting up the threshold of mPAP value at 20 mmHg 
instead of the previous 24 mmHg. According to 
this novel definition, to diagnose pre-capillary PH 
mPAP > 20 mmHg needs to be accompanied by 
pulmonary arterial wedge pressure ≤ 15 mmHg 
and PVR ≥ 3 Wood’s units.
Conclusions
To conclude, kidney function is crucial for the 
proper management of pulmonary thromboembo-
lism. Renal insufficiency increases the risk of CIN 
during the diagnostic process. CIN is observed in 
approximately 13% of patients undergoing CTPA due 
to pulmonary embolism suspicion. Both CKD and 
acute renal injury at pulmonary embolism diagnosis 
are markers of worse short- and long-term prognosis. 
The addition of the criterion: GFR below 60 mL/min, 
to sPESI can potentially improve risk stratification 
in APE. The impaired renal function can improve 
significantly after successful treatment of CTEPH.
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